Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Celularity (CELUW) EBITDA Margin (2020 - 2025)

Historic EBITDA Margin for Celularity (CELUW) over the last 6 years, with Q3 2025 value amounting to 436.66%.

  • Celularity's EBITDA Margin fell 2634700.0% to 436.66% in Q3 2025 from the same period last year, while for Sep 2025 it was 348.6%, marking a year-over-year decrease of 2709000.0%. This contributed to the annual value of 106.78% for FY2024, which is 7546200.0% up from last year.
  • As of Q3 2025, Celularity's EBITDA Margin stood at 436.66%, which was down 2634700.0% from 427.6% recorded in Q2 2025.
  • In the past 5 years, Celularity's EBITDA Margin ranged from a high of 1266.58% in Q2 2022 and a low of 2479.56% during Q3 2023
  • Its 5-year average for EBITDA Margin is 591.05%, with a median of 173.19% in 2024.
  • Per our database at Business Quant, Celularity's EBITDA Margin soared by 31624500bps in 2022 and then crashed by -29077600bps in 2023.
  • Celularity's EBITDA Margin (Quarter) stood at 83.2% in 2021, then surged by 805bps to 586.27% in 2022, then crashed by -90bps to 59.05% in 2023, then plummeted by -3373bps to 1932.56% in 2024, then skyrocketed by 77bps to 436.66% in 2025.
  • Its EBITDA Margin stands at 436.66% for Q3 2025, versus 427.6% for Q2 2025 and 172.84% for Q1 2025.